Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 4/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19844936 | 0.84 | LMNA (0.44) | LMNACA2SMN1; SMN2CA1CA9 | |
| SCHEMBL18034192 | 0.79 | CA2 (0.36) | LMNACA2MMP1 | |
| SCHEMBL775918 | 0.78 | LMNA (0.53) | LMNACA2FFAR1NPC1RECQL | |
| Water SCHEMBL7042206 | 0.77 | CA2 (0.35) | LMNACA2MMP1 | |
| Ammonia Solution, Strong SCHEMBL8156375 | 0.76 | LMNA (0.51) | LMNACA2FFAR1NPC1RECQL | |
| SCHEMBL27519591 | 0.76 | LMNA (0.51) | LMNACA2FFAR1NPC1RECQL | |
| SCHEMBL28130264 | 0.76 | LMNA (0.51) | LMNACA2FFAR1NPC1RECQL | |
| SCHEMBL27408467 | 0.76 | LMNA (0.51) | LMNACA2FFAR1NPC1RECQL | |
| SCHEMBL10598168 | 0.75 | HRH1 (0.43) | LMNANPC1SMN1; SMN2 | |
| SCHEMBL19851311 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037598-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037598-A1 | METHODS OF MAKING AND USING LIGNIN DERIVATIVES | HLCS, LOX, DCXR | LMNA 373/4885CA2 4569/4885FNTA 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.